ASRM 24- EMBRACE: what to expect from embryo viability and clinical outcomes in a niPGT-A program.

ASRM 2024- Academy Studio: EMBRACE: what to expect from embryo viability and clinical outcomes in a niPGT-A program.
Dr. Sakkas explains that as the blastocyst develops, it actively releases DNA into the culture media, with both the quantity and quality of the DNA likely increasing between days 5 and 6. His most recent publication demonstrates that extending embryo culture to day 6 for niPGT-A screening does not compromise embryo viability or affect pregnancy outcomes, making it a safe alternative for patients who wish to avoid embryo biopsy while still pursuing chromosomal testing.